Absci Corporation has unveiled its summer 2025 corporate presentation highlighting its advancements in AI-driven antibody design and lead optimization. The company showcases its state-of-the-art generative AI models used for de novo antibody design, emphasizing the integration of protein language models and antigen structure predictions. These technologies are employed to create epitope-specific binders, enhancing the pharmacological attributes of antibodies while maintaining developability. The presentation also outlines Absci's ongoing clinical trials and early-stage programs, including ABS-101 and ABS-201, as well as its efforts in data-driven AI model training. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.